SLG
ADPT icon

Stanley-Laman Group’s Adaptive Biotechnologies ADPT Stock Holding History

Stanley-Laman Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-114,780
Closed -$929K – 231
2022
Q2 		$929K Buy
114,780
+8,288
+8% +$72.9K 0.17% 169
2022
Q1 		$1.48M Buy
106,492
+45,431
+74% +$714K 0.2% 149
2021
Q4 		$1.71M Buy
61,061
+44,364
+266% +$1.36M 0.2% 152
2021
Q3 		$568K Buy
+16,697
New +$604K 0.07% 221

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stanley-Laman Group's ADPT Position: Q3 2022 in Review

Stanley-Laman Group sold out of Adaptive Biotechnologies (ADPT) in Q3 2022, closing a stake of 114,780 shares — an estimated $929K sold.

Stanley-Laman Group first reported a position in ADPT in Q3 2021 and held it in 4 quarters. The position peaked at $1.71M in Q4 2021. 226 funds tracked by Wall St. Rank hold ADPT as of Q3 2022.

  • Stanley-Laman Group reported no remaining Adaptive Biotechnologies position as of Q3 2022 after selling out during the quarter.
  • Stanley-Laman Group sold 114,780 Adaptive Biotechnologies shares in Q3 2022, an estimated $929K.
  • Stanley-Laman Group first reported a position in Adaptive Biotechnologies in Q3 2021 and held it in 4 quarters.
  • Stanley-Laman Group's Adaptive Biotechnologies position peaked at $1.71M in Q4 2021.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2022.

Based on Stanley-Laman Group's 13F filing for Q3 2022, filed 18 Oct 2022.